<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">MS</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="998" role="article" about="/commodorecompendium/ms" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Multiple Sclerosis</span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background </span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Progressive inflammatory disorder primarily manifesting with demyelination of the central white matter</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Optic neuritis and transverse myelitis (spinal cord lesion) are common presentations </span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Generally develop over a few days; very uncommon to happen suddenly ( e.g., patients will complain about a dark spot appearing in their vision that expands over several days)</span></span></span></span></span></span></li>
</ul>
<p style="margin-left:10px"> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation </span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">MRI w/ and w/o contrast can identify plaques and determine if they are more acute</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">“Active” MS plaque will enhance, and continues to for weeks (even after treatment)</span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Modified MacDonald Criteria:</span></span></b> <span style="font-size:12.0pt"><span style="font-family:Palatino">≥</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">3 characteristic demyelinating lesions (&gt;1 cm, periventricular, infratentorial (brainstem/cerebellum/cord) or juxtacortical in location) with evidence of separation in time (active and chronic)</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">LP can be done to look for oligoclonal bands, IgG index, cell count and protein</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Treat flares with steroids: speeds up recovery but does not improve the degree of recovery</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Would confirm with Neurology (as primary or consulting team) preferred dose, which is often methylpred 1g to start </span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Current guidelines are for optic neuritis to be treated with IV steroids, but recent data challenges this</span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If a patient with known MS has worsening symptoms that are not new, then recrudescence is the likely cause -&gt; infectious/toxic/metabolic workup and imaging is needed </span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Several long-term medications, with common side effects listed below:</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Interferon (SQ injections) – flu-like symptoms, injection site reactions</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Glatiramer acetate (SQ) – injection site reactions</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Fingolimod (PO) – macular edema, liver injury, increased risk of skin cancer</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Teriflunomide (PO) – liver injury, hair loss, immunosuppression, teratogenic</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Dimethyl fumarate (PO) – GI side effects, lymphocytopenia, liver injury</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Natalizumab (IV) – PML concern, immunosuppression</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Ocrelizumab (IV) – contraindicated in active HBV infection, cannot give live vaccines</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Alemtuzumab (IV) – autoimmune disease, rash, headache</span></span></span></span></span></li>
</ul>
</li>
</ul>
</div>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Neuromyelitis Optica and Spectrum Disorder:</span></span></b></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Demyelinating disease due to Ab against aquaporin-4 (on oligodendrocytes)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Classically causes optic neuritis and longitudinally extensive transverse myelitis</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Can be more aggressive than MS and needs steroids but in severe or refractory cases PLEX</span></span></span></span></span></li>
<li><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">NMO antibodies and MS workup as above is done </span></span></span></li>
</ul>
</div>
</div>
</article>
</div>
</div>